Aurobindo Pharma Ltd

Meeting Details

• Dates: September 1–2, 2026, 09:00–17:00 (HKT)
• Type: One-on-one and group meetings; physical in Hong Kong
• Event: Goldman Sachs Asia Leaders Conference Hong Kong 2026

Participants

• Key participants: Company officials and management to attend

Purpose

• Purpose: Investor/analyst meeting at the conference

Meeting Details

• Date: September 01, 2026.
• Time: 09:00 AM to 05:00 PM IST.
• Meeting names: ASHWAMEDH – Elara and India Dialogue 2026.
• Location: Mumbai (physical).

Participants

• Company officials (management representatives) will participate.

Purpose

• Purpose: investor interactions during ASHWAMEDH–Elara and India Dialogue 2026.

FDA inspection update

• FDA completed routine inspection at Lannett Company LLC, a wholly owned subsidiary, Aug 17–21, 2026.
• Four observations were noted, procedural in nature.
• The company will respond within the stipulated timeline.
• No penalties or critical findings disclosed; no immediate impact on operations disclosed.
• Lannett Company LLC is a wholly owned step-down subsidiary of Aurobindo Pharma USA, Inc.

Inspection details

• US FDA conducted routine inspection at AuroPeptides Ltd in Telangana from 17 to 21 August 2026.

Observation

• The inspection concluded with one observation related to facility and equipment maintenance.

Assessment

• The observation does not pertain to data integrity or GMP compliance.

Remediation

• Corrective action has been initiated; formal response will be submitted within the timeline.

Disclosure

• Company will inform stock exchanges of any further developments as required.

FDA update: Raleigh Plant VAI status

• Raleigh Plant (Aurolife Pharma LLC) inspected Mar 24–Apr 10, 2025; Form 483 with 11 observations.
• Facility is classified as Voluntary Action Indicated (VAI) and inspection closed.
• Aurolife Pharma LLC is a wholly owned subsidiary of Aurobindo Pharma.
• Pending inhaler and other dosage form applications from this facility can progress through USFDA review.

Meeting Details

• Date and time: August 19, 2026, 09:00 AM–05:00 PM IST, Mumbai.
• Type: one-on-one and group meetings; mode: physical.
• Event: Motilal Oswal 22nd Annual Global Investor Conference, 2026.
• Participants: company officials (management) to attend.
• Purpose: participation in investor/analyst meeting.

FDA Warning Letter – Unit I

• Unit I of Eugia Pharma Specialities Ltd., wholly owned, received US FDA Warning Letter after OAI.
• No impact on current US market supplies.
• Unit I contributes about 2% to group revenue.
• Company will continue FDA engagement and strengthen compliance.
• Will inform exchanges of further developments.

FDA warning letter to Unit I (Eugia)

• Unit I of Eugia Pharma Specialities Ltd., a wholly owned subsidiary, received a US FDA Warning Letter.
• This follows prior OAI status communicated earlier in May 2026.
• There is no impact on existing US supplies; unit contributes approximately 2% of group revenue.
• Company remains engaged with FDA and will provide further developments to stock exchanges.

Meeting Details

• Date: August 6, 2026; time not disclosed.
• Type/Mode: group earnings conference call; virtual webinar.
• Event/Organizer: Q1 FY27 Earnings Conference Call (Aurobindo Pharma Limited).
• Recording/Transcript: Transcript attached; uploaded on company website.

Participants

• CEO, Aurobindo Pharma Limited (Biosimilars, Vaccines & Peptides).
• CEO, Eugia Pharma Specialities Limited.
• CEO, Aurobindo Pharma, USA.
• CEO, Europe Formulations Business.
• CFO, Aurobindo Pharma Limited.
• Investor Relations & Corporate Communications Team.

Purpose

• Purpose: discuss Q1 FY27 results, outlook, and conduct interactive Q&A.

Availability

• Transcript available on company website; conference recording.
• Conference was recorded.

Target and transaction details

• Target: Auropharm Overseas Limited, a newly incorporated wholly owned subsidiary of Aurobindo Pharma.
• Industry: Pharmaceuticals; country presence: India.
• Turnover: Not disclosed; incorporated August 13, 2026.
• Related party: Yes; wholly owned subsidiary; promoters not involved.
• Objects: Manufacturing and marketing operations in India and abroad.
• Regulatory approvals: None required.
• Timeline: Not applicable.
• Consideration: 100% cash subscription.
• Capital: Rs 10,00,000; 1,00,000 equity shares of Rs 10.
• Ownership: 100% stake.
• Background: Newly incorporated; no three-year turnover history.